The efficacy and mechanism of Panax notoginseng in the treatment of 'anti-platelet drug resistance'

Shaanxi Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients who meet the diagnostic criteria of Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2010 and aspirin semi resistance diagnosis issued by neurology branch of Chinese Medical Association;
•2. Patients who agree to participate in the clinical trial and sign the informed consent form;
•3. Patients aged 45-65 years, with no gender limit and taking single antiplatelet drugs;
•4. Patients with Essen stroke risk score <= 3;
•5. Patients who no longer use traditional Chinese medicine with the function of promoting blood circulation and removing blood stasis in the observation period.

•1. Patients with transient ischemic attack and cerebral infarction need double antibody;
•2. Patients with cerebral infarction, cerebral hemorrhage, cerebral arteritis, brain tumor, brain trauma, brain parasitic disease and rheumatic heart disease;
•3. Patients with bleeding tendency or severe bleeding within 3 months;
•4. Patients with severe liver, kidney, hematopoietic and metabolic diseases;
•5. Patients with disabilities prescribed by law (blindness, deafness, dumb, mental retardation, mental disorder and physical disability caused by other reasons) affect the evaluators of neurological impairment;
•6. Patients who are suspected or have a history of alcohol and drug abuse, or other situations that, according to the judgment of the researchers, have the possibility of reducing or complicating the enrollment;
•7. Patients who are participating in other clinical trials or have participated in other drug clinical trials within 3 months.

发起方

Shaanxi Hospital of Traditional Chinese Medicine